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Aims CT calcium scoring (CTCS) and CT cardiac angiography (CTCA) are widely used in patients with stable chest pain
to exclude significant coronary artery disease (CAD). We aimed to resolve uncertainty about the prevalence of
obstructive coronary artery disease and long-term outcomes in patients with a zero-calcium score (ZCS).
...................................................................................................................................................................................................
Methods
and results
Consecutive patients with stable cardiac symptoms referred for CTCS or CTCS and CTCA from chest pain
clinics to a tertiary cardiothoracic centre were prospectively enrolled. In those with a ZCS, the prevalence of ob-
structive CAD on CTCA was determined. A follow-up for all-cause mortality was obtained from the NHS tracer
service. A total of 3914 patients underwent CTCS of whom 2730 (69.7%) also had a CTCA. Half of the patients
were men (50.3%) with a mean age of 56.9 years. Among patients who had both procedures, a ZCS was present
in 52.2%, with a negative predictive value of 99.5% for excluding >_70% stenosis on CTCA. During a mean follow-
up of 5.2 years, the annual event rate was 0.3% for those with ZCS compared with 1.2% for CS >_1. The presence
of non-calcified atheroma on CTCA in patients with ZCS did not affect the prognostic value (P= 0.98).
...................................................................................................................................................................................................
Conclusion In patients with stable symptoms and a ZCS, obstructive CAD is rare, and prognosis over the long-term is excel-
lent, regardless of whether non-calcified atheroma is identified. A ZCS could reliably be used as a ‘gatekeeper’ in
this patient cohort, obviating the need for further more expensive tests.
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Computed tomography has become a cost-effective, mainstream
technique for excluding coronary artery disease (CAD) in patients
with stable symptoms.1–3 Non-contrast CT calcium scoring (CTCS)
allows detection and quantification of coronary artery calcification
(CAC), but CT coronary angiogram (CTCA) is required for imaging
of calcified and non-calcified plaques as well as quantification of lu-
minal stenoses.4 Often both techniques are performed sequentially.
Numerous studies have demonstrated the very high negative predict-
ive value of a normal CTCA in excluding significant CAD, which is
now recommended in national and international guidelines, including
recently updated UK’s NICE (National Institute for Health and Care
Excellence) guidance.2,5 Based on the findings of landmark trials,6–8 a
recent review has also concluded that CTCA should have a yet
greater role in the diagnostic pathway of patients with stable chest
pain.9 However, CTCA is not only more time consuming and costly
when compared with CTCS, but also requires injection of a contrast
agent, often with administration of beta-blockers adding to the pro-
cedural risk.
A zero-calcium score (ZCS) is associated with an excellent prog-
nosis in asymptomatic people.10,11 However, in symptomatic popula-
tions with stable symptoms and a ZCS, there remains uncertainty
about the prevalence of obstructive CAD and longer term outcomes.
It is further uncertain how prognosis is affected by additional
CTCA.12
Early studies of CTCS in patients with angina found that a ZCS was
associated with a 2% prevalence of obstructive CAD (>50% stenosis)
on invasive coronary angiography (ICA).11 But, more recent studies
have reported up to 19% prevalence rate using CTCA.13,14 This has
led to recommendations of using CTCA despite a ZCS.2 Although a
large multi-centre study reported a low prevalence (3.5%) of more
than 50% stenosis in patients with a ZCS and no effect on mortality
at 2 years compared with patients with obstructive disease, there
was increase in composite end-point driven with revascularisation
leading the authors to conclude that a ZCS is associated with ob-
structive CAD and increased cardiovascular events.15
The main objective of this study was to determine the prevalence
of significant CAD (>_70% diameter stenosis) in patients with ZCS
and prognostic value of the latter in a large cohort of patients with
stable symptoms over a long-term follow-up. A secondary objective
was to determine prognosis stratified by calcium score in groups with
and without significant CAD on CTCA.
Methods
This is an observational cohort study from prospectively collected data in
Harefield Hospital Cardiac CT Registry from patients referred to a tertiary
cardiac centre from six Rapid Access Chest Pain clinics (RACPC) in dif-
ferent hospitals for a cardiac CT. Consecutive patients referred for
cardiac CT who presented with stable chest pain or dyspnoea with no
prior history of CAD were included in the study. Those with previous
percutaneous intervention, coronary artery bypass surgery, or known
conditions in an advanced stage such as heart failure, arrhythmia, cancer,
valve disease, and pulmonary disease were excluded. Also, patients who
had a CTCA but images were non-interpretable due to artefacts (n= 22)
were excluded from the analysis of CAD, but the calcium score
was included for the purpose of prognosis. Appropriate NHS (National
Health Service) research ethics approval was obtained (IRAS Project ID:
199531).
The data was divided into two groups: Group A, containing patients
from 2007 to 2015 who underwent both CTCS and CTCA, and Group
B, containing patients from 2003 to 2015, who underwent only CTCS.
The decision to perform a CTCA after CTCS was based on NICE
(National Institute for Health and Care Excellence) guidance for local pa-
tients,16 while patients from other hospitals had both scans performed at
the same time as requested by the referring cardiologists. Generally, pa-
tients with low to intermediate pre-test probability were referred for car-
diac CT (to Harefield Hospital) but some patients with higher probability
but atypical symptoms or those who preferred a non-invasive test were
also referred. In both groups, further investigations in the form of stress
imaging or ICA were performed, as clinically required, but only analysed
in those patients with a ZCS.
The chest pain was labelled as non-cardiac, atypical, or typical angina as
per standard criteria.2 History of exertional dyspnoea was classified as
typical chest pain for the calculation of pre-test probability (PTP).17 The
PTP of each patient was calculated using the Duke’s criteria18 and cate-
gorised as very low (<10%), low (10–29%), intermediate (30–60%), high
(61–90%), and very high risk (>90%) on the basis of type of chest pain,
age, sex, and presence or absence of high cholesterol, diabetes, and his-
tory of smoking.16 Smokers were defined as those who were currently
smoking or have quit within the last 3 years. Hypercholesterolaemia was
defined as total serum cholesterol of greater than 5.5mmol/L, or if the pa-
tient was on statin therapy. Patients were considered hypertensive or dia-
betic if they had an extant diagnosis or were on anti-hypertensive or
diabetic medication. The family history of premature CAD was con-
sidered to be present if this was known in a first-degree male relative
age <55 years or female relative age <60 years.
The CTCS studies were performed on either a 4-slice (Siemens
Volume Zoom) (from 2003 to 2006) or a 64-slice CT scanner (Toshiba
Aquilion) (from 2007 to 2015) with images acquired using 120 kVp,
300–600 mAs, prospective ECG gating, and 3/3 mm reconstructions.
Standard Agatston’s method was used to calculate the calcium score
(CS).19 The analysis was performed on either a Siemens’ Virtuoso
(Siemens Medical Systems, Germany) or Vitrea (Vital Images, Minnesota)
workstation. The mean effective radiation dose was 0.9 mSv for men and
1.4mSv for women, using a conversion factor of 0.014. The calcium
scores were categorised as 0, between 1–100, 101–400, and >400 for
the purpose of analysis. The patients who only had a CTCS scan were
included for follow-up purpose but not for analysing the presence or ab-
sence of obstructive CAD.
All CTCA scans were performed on a 64-slice multi-detector CT
scanner (Toshiba Aquilion) using 100 or 120 kVp and 400–600 mAs de-
pending upon patient’s body weight. Patients received oral or intravenous
metoprolol to reduce the heart rate to <65 bpm and 800 mg of sublingual
glyceryl trinitrate for vasodilatation in the absence of contraindications.
70–90 mL of non-ionic, low osmolar contrast (iopromide, Ultravist 370,
Bayer Healthcare) was administered intravenously as the contrast media.
The scanner generated the best phase image data set with least motion
automatically, and further reconstructions were performed, as required,
using 0.5 collimation and 0.3 mm slice-interval. The mean radiation dose
Prevalence of obstructive coronary artery disease 923
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..was 7.2 and 13.1 mSv for prospective and retrospective gated scans re-
spectively. Interpretation of CTCA was performed as per SCCT guide-
lines20 by level 3 trained and experienced cardiac radiologists and
cardiologists. All plaques were evaluated using orthogonal and curved
multi-planar reformats (MPRs) and considered to be present if visually en-
croaching into the lumen of coronary artery. Plaques were classified as
calcified, partially-calcified, or non-calcified and described in a modified
16-segment coronary artery model.20 The degree of CAD was classified
as being absent, mild (<50% in luminal diameter), moderate (50–69%
stenosis), and severe (>_50 in the left main stem and >_70% in other coron-
ary arteries) stenosis.
Patients found to have moderate or severe stenosis on CTCA
were recommended to have further evaluation with stress imaging or
ICA respectively, but the final decision was left to their cardiologist/
physician.
All patients were followed up for all-cause mortality through the UK’s
Health & Social Care Information Centre via the NHS tracing service,
which was available for 97% of the patients. Further follow-up of patients
with ZCS who died was obtained from their general practitioners and
hospital records.
Statistical analysis
The continuous variables are presented as mean ± SD or median (inter-
quartile range), and comparison between groups was performed using
the unpaired t-test or the Mann–Whitney test. The categorical variables
are presented as frequencies with percentages, and the v2 or Fisher’s
exact test was used to compare between groups. A survival analysis was
performed as percentage surviving at 5 and 13 years using the Kaplan–
Meier method. Kaplan–Meier survival curves were drawn by presence or
absence of CS, presence or absence of CAD on CTCA in ZCS group, CS
categories, and CTCA stenosis severity.
Cox regression was performed in Group A patients for varying de-
gree of CS and CTCA stenosis severity to assess their association with
survival times. Any CS of >100 was considered as one category for
this purpose due to a smaller number of patients with CS >400. The
multivariate analysis was performed after adjusting for age, gender,
and risk factors (hypertension, diabetes, smoking, high cholesterol, and
family history) as three different models: Model 1, including patients
with CS >_1 and CAD >_25%; Model 2, including patients with CS >_100
and CAD >_50%; and model 3 including patients with CS >_100 and
CAD >70%.
All analysis was performed using STATA version 13.0 (StataCorp,
College Station, Texas). A two-tailed P-value of <0.05 was considered
statistically significant.
Results
Patient characteristics
A total of 3914 patients fulfilled the inclusion criteria (Table 1). The
mean age was 56.9 years (±12.4), and 50.3% of patients were men.
Half of the patients (50.5%) had a ZCS, but the prevalence varied in-
versely with the PTP of disease, being highest (58.9%) in those with
PTP of <30% and lowest (14%) in PTP of >60%. Patients with ZCS
were less likely to be male, or to have hypertension, diabetes, high
cholesterol, or typical chest pain.
.................................................................................................
Table 1 Baseline characteristics of patients with a
zero-calcium score and those with a calcium score of1
in both groups and CTCA stenosis severity in group A
patients
Variable All
patients
CS5 0 CS 1 P-value
Number (%) 3914 1978 (50.5) 1936 (49.5)
Age (years), Mean ± SD 56.9 ± 12.4 51.2 ± 11.4 62.8 ± 10.5 <0.001
Male sex (%) 1969 (50.3) 862 (43.6) 1107 (57.2) <0.001
BMI (kg/m2), Mean ± SD 28.8 ± 5.9 28.6 ± 6.0 29.0 ± 6.0 0.17
Hypertension—N (%) 1563 (39.9) 574 (29.0) 989 (51.1) <0.001
Diabetes—N (%) 486 (12.4) 150 (7.6) 336 (17.4) <0.001
High cholesterol—N (%) 1664 (42.5) 689 (34.8) 975 (50.4) <0.001
Current smoker—N (%) 595 (15.2) 299 (15.1) 296 (15.3) 0.88
Family history—N (%) 1258 (38.8) 665 (40.4) 593 (37.1) 0.06
Chest pain <0.001
Typical—N (%) 723 (18.5) 303 (15.3) 420 (21.7)
Atypical—N (%) 1614 (41.2) 876 (44.3) 738 (38.1)
Non-anginal—N (%) 992 (25.3) 533 (26.9) 459 (23.7)
Dyspnoea—N (%) 585 (14.9) 266 (13.5) 319 (16.4)
PTP %—Median [IQR] 37 (16, 67) 22 [10, 46] 58 [31, 79] <0.001
PTP category <0.001
Very low—N (%) 578 (14.8) 488 (24.7) 90 (4.7)
Low—N (%) 1042 (26.6) 677 (34.2) 365 (18.9)
Intermediate—N (%) 1086 (27.8) 537 (27.2) 549 (28.4)
High—N (%) 936 (23.9) 241 (12.2) 695 (35.8)
Very high—N (%) 272 (6.9) 35 (1.8) 237 (12.2)
Calcium score—
Median [IQR]
0 (0, 96) 0 [0, 0] 97 [24, 338] –
Group A Stenosis
severity
2730 (69.7) 1426 (52.2) 1304 (47.8) <0.001
Absent—N (%) 1320 (48.4) 1282 (89.9) 38 (3.0)
Mild—N (%) 935 (34.3) 120 (8.4) 815 (62.5)
Moderate—N (%) 195 (7.1) 17 (1.2) 178 (13.7)
Severe—N (%) 278 (10.2) 7 (0.5) 271 (20.8)
Died, N (%) 147 (3.8) 28 (1.4) 119 (6.1) <0.0001
CS, calcium score; CTCA, CT cardiac angiogram; BMI, body mass index; PTP,
pre-test probability.
.................................................................................................
Table 2 Baseline characteristics of patients with a
zero calcium score and absence or presence of50%
stenosis on CTCA
Variable CAD <50% CAD 50% P-value
(n 5 1402) (n5 24)
Age (years), Mean ± SD 49.4 ± 11.4 52.9 ± 9.3 0.08
Male sex (%) 603 (43) 12 (50) 0.49
Typical chest pain or dyspnoea, N (%) 472 (34) 11 (46) 0.21
Hypertension—N (%) 402 (29) 9 (38) 0.34
Diabetes—N (%) 104 (7.4) 3 (13) 0.35
High cholesterol—N (%) 471 (34) 7 (29) 0.65
Current smoker—N (%) 223 (16) 7 (29) 0.08
Family history—N (%) 526 (38) 8 (33) 0.70
PTP (%)—Mean ± SD 28.9 ± 24.7 40.8 ± 29.8 0.06
CAD, coronary artery disease; PTP, pre-test probability.
924 T.K. Mittal et al.
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..Among the study cohort, 2730 (69.7%) had both CTCS and
CTCA (Group A). In this group, a ZCS was seen in 1426 (52.2%) of
whom 17 (1.2%) had moderate stenoses, and 7 (0.5%) had severe
stenoses on CTCA. In women, who had higher prevalence of a ZCS
(56.4%, P< 0.0001), no difference was seen in the prevalence of mod-
erate or severe stenosis compared with man (12 cases each,
P= 0.493) All patients with >50% stenosis underwent subsequent
stress imaging or ICA confirming flow limiting stenosis in only four pa-
tients (0.3%). The negative predictive value of ZCS for excluding se-
vere CTCA stenosis was 99.5%.
There were 1408 (51.6%) patients who had some degree of
atheromatous plaques in the coronary arteries on CTCA
(Table 1) causing varying degree of stenosis. Detailed plaque analysis
was available in 2704 patients. There were 3889 coronary artery seg-
ments (9.6%) containing predominantly calcified, partially-calcified,
and non-calcified plaques in 50.6, 39.5, and 9.9% segments
respectively.
The median PTP of coronary disease in Group A patients was 37%
(IQR = 14–66%) with severe CAD identified in 10.2% patients on
CTCA. The seven patients with ZCS but severe CTCA stenosis
Figure 1 Kaplan–Meier survival curves by (A) presence or absence of any coronary artery calcium score, and (B) presence or absence of any
degree of non-calcified atheroma on CTCA in patients with zero calcium score.
Prevalence of obstructive coronary artery disease 925
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..were distributed across all PTP categories (P= 0.732). In patients
with a ZCS, no significant difference was found in the baseline charac-
teristics or risk factors in those with or without >_50% CTCA stenosis
(Table 2).
Follow-up and survival
In the 13-year follow-up period (mean = 5.2 ± 2.8 years), a total of
147 deaths (3.8%) were observed from any cause. There were 28
deaths in patients with ZCS (1.4%; annual event rate, 0.3) compared
with 119 deaths (6.1%; annual event rate, 1.2) in those with a CS >_1
(OR = 4.6, 95% CI = 3.0, 6.0; P< 0.0001). None of the patients with
ZCS died of a coronary event.
Kaplan–Meier survival estimates in groups with a ZCS and a
calcium score >_1 were 99.0% (95% CI -98.3, 99.4) and 94.5%
(95% CI -92.9, 95.5, P< 0.001) at 5 years, and 95.5% (95% CI -92.1,
97.5) and 84.0% (95% CI -78.6, 88.2) at 13 years (Figure 1A).
Among patients with a ZCS, Kaplan–Meier survival estimates were
unaffected by the presence of non-calcified atheroma on CTCA
(P= 0.98, Figure 1B).
Among Group A patients, both calcium score (Figure 2A)
and CTCA stenosis severity (Figure 2B) were inversely related to
survival. Cox-regression analysis confirmed stepwise associations
of increasing calcium score and increasing CAD severity with the haz-
ard of death (Table 3). However, in the adjusted Cox analysis only
Figure 2 Kaplan–Meier survival curves by (A) calcium score category, and (B) CTCA stenosis severity.
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the calcium score showed significant association with the hazard of
death.
Discussion
In this large cohort study of patients with suspected stable coron-
ary artery disease, a zero-calcium score reliably excluded obstruct-
ive coronary artery disease with a negative predictive value of 99.5%.
It also predicted an excellent long-term prognosis, effectively
ruling out the risk of coronary events during follow-up for 13 years.
These anatomic and prognostic data show that CT calcium scoring
is a robust method for identifying low-risk patients and question
the need for further testing when the score is zero.
Among patients with a ZCS, the prevalence of obstructive CAD,
with >50% luminal narrowing, has been the subject of debate. The
prevalence by invasive coronary angiography is very low,11 yet in two
CTCA cohorts, comprising 668 and 291 patients, prevalence rates of
7 and 19% were reported.13,14 In these studies, however, up to 38%
of the patients had presented acutely, unlike more recent CTCA
studies12,15,21 that exclusively included stable patients when the
prevalence of obstructive lesions (>50% luminal narrowing) in pa-
tients with a ZCS was much lower. Indeed, allowing for the low posi-
tive predictive value of CTCA,22 the prevalence data in these more
recent studies are comparable to those we report. In our patients,
we could confirm the diagnosis of obstructive disease by invasive cor-
onary angiography or stress imaging, lending further weight to the val-
idity of our findings. The 99.5% negative predictive value of a zero
calcium score compares favourably with CTCA23 and is considerably
higher compared to stress imaging tests,24 questioning the need for
further testing to rule out coronary disease when the calcium score
is zero.
The proportion of patients with stable symptoms having a ZCS
largely depends upon the pre-test probability as shown in this study.
While in patients with typical angina undergoing ICA, a ZCS was pre-
sent in up to 20% patients,11 the recent CTCA studies12,15,21,25,26
have demonstrated a prevalence of between 40 and 53% in patients
with a mean PTP of between 40 and 45%. It is also now being realised
that the PTP calculation methods developed in 1980’s and 1990’s
overpredict the prevalence of significant CAD based on both newer
ICA27 as well as CTCA data,28 at least in the developed countries.
Downgrading the PTP by newer methods may result in increased
proportion of ZCS in the low to intermediate PTP groups.
It was a strength of our study that medium and long-term prognos-
tic data were available showing that a ZCS in patients with stable
chest pain was associated not only with a very low prevalence of ob-
structive coronary disease but also with excellent long-term survival.
Previous studies in asymptomatic patients have also reported favour-
able survival but in symptomatic patients, the prognostic data are re-
stricted to the first 2 years when survival exceeds 99% in patients
with a ZCS.15 We now confirm that estimated survival remains at
this level after 5 years, falling to only 95.5% after 13 years.
Importantly, these survival data in patients with a zero calcium score
are unaffected by the presence of non-calcified atheroma on the CT
coronary angiogram, a finding that is consistent with previous reports,
the CONFIRM study, for example, reporting a 0.4% 2-year mortality
irrespective of CTCA findings.15 Although a subsequent analysis of
CONFIRM data revealed a trend towards increasing combined event
rate of all-cause mortality and myocardial infarction over a shorter
median follow-up period of 25 months, it was not statistically signifi-
cant (P= 0.07).29 These findings reassure that in patients with chest
pain and a ZCS, the long-term prognosis is excellent and unlikely to
be improved by further cardiac investigation and treatment. As the
calcium score rises above zero, however, so does the risk of ob-
structive coronary disease and death.12,15,25,29–32 Genders et al.27
found the calcium score improved probability estimates of obstruct-
ive coronary disease, but our findings suggest that the calcium score
may be a stronger predictor of events, perhaps reflecting the limita-
tions of CTCA for quantifying lesion severity.
There is no doubt that CTCA provides comprehensive assess-
ment of CAD with demonstration of plaques with quantification of
stenosis, thus providing greater accuracy for diagnosis and prognosis.
CTCS, on the other hand is a relatively crude technique, but is much
simpler to perform without the need for contrast and beta-blockers,
as well requiring less time for reporting. The 2010 NICE chest pain
guideline16 had recommended CTCS as the initial test to rule out
coronary disease in low-risk individuals, but the recently updated
guidance5 advises CTCA as the first-line investigation for all patients
with angina, independently of CTCS. Our data suggest that even
amongst patients with typical or atypical angina, as many as 50% will
have a ZCS with an excellent prognosis. As CTCS is easy to perform,
it can be readily integrated into busy outpatient care and we would
argue that it can reasonably be retained as a gatekeeper to CTCA
when implementing the new NICE guideline.
Strengths of this study include the large cohort size and the long
follow-up period. However, it was an observational study based in
a single-centre, and this limitation must be acknowledged. A further
limitation was the self-reporting of risk factors with the potential to
................................... ......................................
.................................................................................................
Table 3 Cox regression analysis demonstrating haz-
ard ratios (95% confidence intervals) for mortality
stratified by calcium score and severity of obstructive
coronary artery disease
Univariable analysis Multivariable analysisa
Variable HR (95% CI) P-value HR (95% CI) P-value
Model 1: CS >_ 1 and CAD >_ 25%
CS >_ 1 3.4 (1.9, 5.8) <0.0001 1.9 (1.2, 3.1) 0.004
CAD >_ 25% 1.1 (1.0, 1.1) 0.026 1.0 (0.9, 1.0) 0.41
Model 2: CS >_ 100 and CAD >_ 50%
CS >_ 100 5.3 (3.2, 8.5) <0.0001 2.4 (1.3, 4.3) 0.006
CAD >_ 50% 3.6 (2.2, 5.8) <0.0001 1.5 (0.9, 2.7) 0.14
Model 3: CS >_ 100 and CAD >_ 70%
CS >_ 100 5.3 (3.2, 8.5) <0.0001 2.4 (1.3, 4.4) 0.005
CAD >_ 70% 3.9 (2.4, 6.4) <0.0001 1.6 (0.9, 2.9) 0.11
CS, calcium score; CAD, coronary artery disease severity on CT cardiac
angiogram.
aMultivariable analysis includes an adjustment for age, sex, chest pain typicality,
hypertension, diabetes mellitus, high cholesterol, current smoking, and family
history.
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.
undermine the accuracy of the pre-test probability of disease esti-
mates. We were unable to determine the cause of death in all cases,
except in those with ZCS, and have thus used all-cause mortality as
the main outcome. We were also not able to identify non-fatal
events. Like in other similar studies, the outcome results did not ex-
clude those who underwent revascularisation and did not consider
the effect of any preventative medical therapy. This could affect the
outcome, particularly in those in ZCS group who were found to have
flow limiting stenosis and underwent revascularisation.
In conclusion, patients with stable symptoms and a zero-calcium
score have a very low prevalence of obstructive CAD and an excel-
lent prognosis over the medium to long-term. As the calcium
score rises above zero, so does the prevalence of coronary disease
and the risk of death. Calcium scoring has the potential to enhance
risk management in patients with undiagnosed chest pain, a zero-
score questioning the need for a further cardiac investigation. Indeed,
a zero-calcium score might be seen as a gatekeeper, with further test-
ing reserved for patients with positive scores.
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